Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 66.8383
- Book/Share 17.8792
- PB 18.8761
- Debt/Equity 5.6749
- CurrentRatio 1.2797
- ROIC 0.1044
- MktCap 181731841656.0
- FreeCF/Share 21.448
- PFCF 15.7494
- PE 25.92
- Debt/Assets 0.6056
- DivYield 0.0282
- ROE 0.9619
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMGN | Truist | -- | Hold | -- | $318 | Nov. 24, 2025 |
| Initiation | AMGN | Scotiabank | -- | Sector Outperform | -- | $385 | Nov. 13, 2025 |
| Resumed | AMGN | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
| Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
| Initiation | AMGN | Cantor Fitzgerald | -- | Overweight | -- | $405 | Sept. 27, 2024 |
News
Final Trades: Amgen, Sabra Health Care and Kinsale Capital Group
Published: April 03, 2025 by: CNBC Television
Sentiment: Neutral
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
Read More
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now
Published: April 03, 2025 by: The Motley Fool
Sentiment: Negative
As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. The outlook for the economy is worrisome, as trade wars and promised tariffs could lead to disaster for many businesses.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
GILD or AMGN: Which Is the Better Value Stock Right Now?
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Trade Tracker: Kevin Simpson buys Howmet, buys more Amgen
Published: March 28, 2025 by: CNBC Television
Sentiment: Neutral
Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest portfolio buys.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
Published: March 27, 2025 by: Proactive Investors
Sentiment: Negative
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Read More
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity
Published: March 26, 2025 by: CNBC Television
Sentiment: Positive
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
Read More
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Read More
Prediction: These 2 Stocks Will Outperform the Market Through 2030
Published: March 18, 2025 by: The Motley Fool
Sentiment: Positive
Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
HALO vs. AMGN: Which Stock Is the Better Value Option?
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.
Read More
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Published: March 07, 2025 by: FXEmpire
Sentiment: Neutral
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
Read More
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
Read More
Trade Tracker: Joe Terranova sells the XBI, buys Amgen
Published: March 05, 2025 by: CNBC Television
Sentiment: Neutral
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Read More
Amgen starts two critical late-stage trials for weight loss drug MariTide
Published: March 05, 2025 by: CNBC
Sentiment: Positive
Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly, which are weekly injectables.
Read More
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
THOUSAND OAKS, Calif. , Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 45th Annual TD Cowen Health Care Conference at 9:10 a.m.
Read More
This Could Be the Best GLP-1 Stock to Buy in 2025
Published: February 28, 2025 by: The Motley Fool
Sentiment: Neutral
The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype around weight loss drugs isn't new, but when people are losing more than 20% of their body weight, it creates considerable enthusiasm.
Read More
Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG
Published: February 27, 2025 by: CNBC Television
Sentiment: Neutral
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.
Read More
Final Trades: Berkshire Hathaway, Amgen, Prologis and 3M
Published: February 27, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Amgen Stock: Why I Still Rate It A 'Buy'
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen Stock: Why I Still Rate It A 'Buy'
Read More
10 Undervalued Dividend Growth Stocks: February 2025
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.
Read More
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
Published: February 25, 2025 by: The Motley Fool
Sentiment: Positive
How is the Dow Jones Industrial Average (^DJI 0.08%) performing this year? It might depend on whether you view the proverbial glass of water as half-empty or half-full.
Read More
Amgen plans $200 million investment in India site, CEO says
Published: February 24, 2025 by: Reuters
Sentiment: Positive
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the inauguration of the site.
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen, Inc. (NASDAQ:AMGN ) Citi's 2025 Virtual Oncology Leadership Summit Conference Call February 19, 2025 3:00 PM ET Company Participants Jean-Charles Soria - Senior Vice President of R&D Justin Claeys - Vice President of Investor Relations Conference Call Participants Geoffrey Meacham - Citigroup Geoffrey Meacham Hello, good afternoon. My name is Geoff Meacham.
Read More
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m.
Read More
Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen, Inc. (NASDAQ:AMGN ) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Company Participants Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - Head of Investor Relations Casey Capparelli - Investor Relations Conference Call Participants Jay Olson - Oppenheimer & Co. Jay Olson Hello, everyone. I'm Jay Olson, one of the biotech analysts at Oppenheimer, and it's a pleasure to welcome you to Oppenheimer's 35th Annual Healthcare Conference.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000